3月11日 - ** 癌症疗法开发商Coeptis Therapeutics的COEP.O股价上涨2.3%至11.15美元
** Coeptis Therapeutics表示， (link)，该公司已获得细胞疗法平台GEAR的全球开发和商业化许可权。
** 作为与 VyGen-Bio 协议的一部分，Coeptis 成立了一家新的控股子公司 GEAR Therapeutics，以推进该技术的应用。
** GEAR(Gene Edited Antibody Resistant) 细胞疗法平台可改造免疫细胞，使其有效靶向并消灭癌细胞，而不会被治疗过程中服用的抗体中和。
** 截至上次收盘，COEP 在过去 12 个月中上涨了 13.5
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.